#United States #Dana Point #Pacific Software #SpectroChip #PurMinds

Pacific Software Inc. and SpectroChip: Innovating Neuromedicine

In an exciting development for healthcare, Pacific Software Inc. (OTC: PFSF) has completed its acquisition of 10763942 Canada Inc., doing business as PurMinds NeuroPharma. This acquisition not only marks a strategic expansion for Pacific Software but also initiates a transformative partnership with SpectroChip Global Inc.. This alliance is set to reshape the landscape of precision neuromedicine through advanced diagnostic technologies.

The Transaction and New Leadership

The recent transaction, which positions PurMinds at the forefront of neurological and psychiatric treatment innovation, involved acquiring all outstanding shares of PurMinds. The management team from PurMinds has seamlessly transitioned into leadership roles at Pacific Software and is considering a rebranding to PurMinds Enterprises, pending approval from FINRA. This change aligns with their ambition to fortify the corporate identity around their cutting-edge neuropharmaceutical developments.

The Partnership with SpectroChip

Today also marked the announcement of an exclusive global partnership with SpectroChip, known for their pioneering photonic chip-based diagnostic solutions. This collaboration will integrate PurMinds's expertise in precision neuromedicine, including biomarker discovery and multi-omics studies, with SpectroChip's innovative diagnostic technology. The goal is to develop point-of-care testing (POCT) solutions that are rapid, intelligent, and cost-effective—aiming to deliver hospital-grade diagnostics directly to patients' bedsides.

Janet Qi, the Founder and CEO of PurMinds, expressed her enthusiasm for this partnership, emphasizing its potential to generate new revenue streams and enhance the future of precision medicine. "This partnership signifies another step forward towards a healthcare ecosystem characterized by predictive, preventive, personalized, and participatory medicine," Qi stated.

Benefits of the Collaboration

The integration of PurMinds's clinical capabilities with SpectroChip's technologies enables the development of tools for better patient stratification, monitoring, and the collection of longitudinal health data. The expected benefits include:

• - Faster diagnosis times: Patients will receive quicker assessments and be able to utilize treatments more rapidly, potentially improving outcomes significantly.
• - Lower costs: The efficiencies gained through these technologies could result in significant cost savings across healthcare systems.
• - Increased success rates in clinical trials: With enhanced tools for monitoring and data collection, the potential for higher success rates in clinical trials is promising, thus encouraging innovation in treatments.

Dr. Kevin Ko, the founder of SpectroChip, highlighted their commitment to leading the evolution of point-of-care diagnostics. He remarked, "Our partnership with PurMinds allows us to leverage their deep expertise in biomarker validation and therapeutic development to advance our diagnostic platform further. Together, we aspire to redefine precision diagnostics and enhance healthcare accessibility globally."

About PurMinds and SpectroChip

PurMinds NeuroPharma is an innovative company focused on developing solutions for neurological and psychiatric disorders through a precision medicine model. Their clinical pipeline includes promising psychoactive compounds alongside proprietary small molecules aimed at restoring neuronal functions and addressing critical patient needs.

On the other hand, SpectroChip has introduced the first photonic chip-based POCT diagnostic platform, which amalgamates spectrophotometry, chromatography, and lateral flow immunoassays into a compact device. This technology promises laboratory-grade precision that is portable and compatible across various applications in healthcare and beyond.

Conclusion

The partnership between Pacific Software, PurMinds, and SpectroChip heralds a new era in healthcare innovation. With a focus on delivering effective and efficient clinical solutions, these organizations are set to make significant strides in the field of neuromedicine. As they prepare for future developments and launch timelines, the industry watches closely for the transformative impact of this collaboration on patient care.

For further updates and more information on this partnership, interested parties can visit PurMinds and SpectroChip.